MedTrace Logo

The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART

NCT03980665 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-09-14

No results posted yet for this study

Summary

To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.

Conditions

Interventions

DRUG

Arsenic Trioxide

a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia

Sponsors & Collaborators

  • Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences

    collaborator UNKNOWN

  • Guangzhou 8th People's Hospital

    lead OTHER

Principal Investigators

  • Weiping Cai, Bachelor · Guangzhou 8th People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980665 on ClinicalTrials.gov